SCHEMBL4098392

SCHEMBL4098392

Cc1c(S(=O)(=O)Nc2ccc(I)cc2)csc1C(=O)Nc1ccccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.56
ALOX5 P09917 1/20 0.56
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
NPC1 O15118 2/20 0.54
RPA1 P27694 1/20 0.53
GFER P55789 1/20 0.53
EDNRB P24530 1/20 0.48
EDNRA P25101 1/20 0.48
ALDH1A1 P00352 5/20 0.45
HPGD P15428 3/20 0.45
HSD17B10 Q99714 3/20 0.45
MIF P14174 1/20 0.45
KDM4E B2RXH2 2/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
RAB9A P51151 1/20 0.41
MCL1 Q07820 1/20 0.41
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087296 0.91 RPA1 (0.66) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL4106217 0.85 MEN1 (0.55) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL4103109 0.82 MEN1 (0.52) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL4097117 0.80 RPA1 (0.55) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL13870878 0.79 MEN1 (0.88) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL4102827 0.77 PTGES (0.83) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL6835804 0.73 RPA1 (0.46) PTGESALOX5MEN1KMT2ANPC1
SCHEMBL6818216 0.72 MAPT (0.49) PTGESALOX5MEN1KMT2ARPA1
SCHEMBL6818512 0.71 RPA1 (0.51) PTGESALOX5RPA1GFERHPGD
SCHEMBL6833237 0.71 RAB9A (0.45) PTGESALOX5MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
EP-1758571-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115374-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 PTGES 2364/4885ALOX5 254/4885MEN1 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.